Johnson & Johnson (J&J) entered a definitive agreement to acquire Halda Therapeutics for USD 3.05 billion, gaining its RIPTAC platform focusing on induced proximity strategies. The lead candidate HLD-0915 is an oral first-in-class molecule targeting AR and BRD4 in metastatic castration resistant prostate cancer (mCRPC) and currently in Phase I/II, showing PSA reduction and circulating tumour DNA clearance in heavily pretreated patients. The technology forces complex formation between cancer-specific proteins and essential survival effectors, leading to selective cell death with minimal impact on normal cells through a hold-and-kill mechanism.

Halda raised USD 202 million in total financing through Series A and B rounds, supporting the rapid progression from 2019 founding to clinical validation within 6 years, compared to the 18-year development timeline for the first PROTAC (a different molecular glue modality). The acquisition demonstrates the maturation of the induced proximity field, expanding beyond protein degradation to functional inhibition applications with potential across solid and haematological malignancies. J&J thus gains a novel mechanism addressing treatment resistance in prostate cancer, where AR signalling remains a key driver despite existing therapies, with planned combination studies and label expansion opportunities across its oncology pipeline.

PharmCube's NextBiopharm® database, Kolm Therapeutics is the only other company with induced proximity candidates, and got acquired by Roche earlier this year. Click here to request a free trial for NextBiopharm®.